Innate Pharma: Jennifer Butler appointed as Executive VP, General Manager, US
12 Mars 2019 - 07:00AM
Innate Pharma: Jennifer Butler appointed as Executive VP, General
Manager, US
Innate Pharma announces the appointment
of Jennifer Butler as Executive Vice President, General
Manager, US
- Commercial industry leader with immuno-oncology product
launch experience joins Innate’s Executive Committee
- General Manager will lead the
Lumoxiti® transition to Innate
Pharma from AstraZeneca including build-out of commercial and
medical affairs operations
- Global commercial leadership further strengthened with
the additions of Hélène Arditti as Strategic Executive Advisor and
Guillaume Gimonet as Senior Director, Launch Excellence
Marseille,
France, March 12, 2019, 7:00 AM CEST
Innate Pharma SA (the “Company”, “Innate” -
Euronext Paris: FR0010331421 – IPH) today announces the appointment
of commercial industry leader Jennifer Butler as Executive Vice
President and General Manager of Innate Pharma US Inc., effective
March 11 2019. Ms. Butler brings more than 20 years of strategic
marketing and commercial leadership expertise across several
therapeutic areas. Throughout her career, Ms. Butler has led and
built multiple global and US commercial teams, including the
product launch of IMFINZI®/durvalumab (anti-PD-L1) while serving as
the Global Commercial Head of Immuno-oncology at AstraZeneca.
Ms. Butler will lead Innate Pharma’s US corporate activities
focusing on the establishment of the Company’s US operations to
fully support the commercialization of Lumoxiti®. She will also
collaborate with Innate’s global commercial team to support
Lumoxiti’s future potential launches in Europe and life cycle
management. Ms. Butler will be part of the Executive Committee of
Innate Pharma and report directly into Mondher Mahjoubi, Chief
Executive Officer.
“We welcome Jennifer to the Innate team. Her
skills and leadership will be invaluable to Innate to support our
expansion into the US and the execution of our goals for the
commercialization of Lumoxiti®,” commented Mondher
Mahjoubi, Chief Executive Officer of Innate Pharma.
“Jennifer is an accomplished and successful commercial leader with
deep expertise in immuno-oncology. She has an impressive track
record of establishing commercial operations and successfully
executing drug launches in the US. This is an exciting and
rewarding year for Innate as we not only have the ability to
discover and develop potential novel therapeutics in high unmet
need patient populations, but are now able to provide the first FDA
approved alternative treatment in 20 years to third line hairy cell
leukaemia patients.”
Ms. Butler will be joining Innate from Tessa
Therapeutics, a clinical-stage oncology company, where she served
as Chief Business Officer, Chief Commercial Officer and Head of US
operations, responsible for global business development and
commercial strategy. Prior to her role at Tessa Therapeutics, she
served for more than 10 years in various commercial roles with
increasing responsibility at AstraZeneca/MedImmune. While at
AstraZeneca, Ms. Butler was the Global Commercial Head of
Immuno-Oncology, where she led the global commercial team preparing
for the company’s first Immuno-Oncology launches with IMFINZI® in
bladder cancer. Ms. Butler also previously worked in strategic
healthcare consulting and as an analyst in Equity Capital Markets
at Merrill Lynch.
“I am excited to be joining Innate Pharma at
this important inflection point as it transitions from a R&D
organization into a fully-integrated biotechnology company,”
commented Jennifer Butler. “We are in a unique and
privileged position for Innate to build an oncology commercial
infrastructure for Lumoxiti® that we will be able to leverage for
the launch, subject to regulatory approval in the US, of our
proprietary asset IPH4102. I look forward to leading a
collaborative and seamless transition of commercial operations from
AstraZeneca for Lumoxiti® while building out Innate’s commercial
and medical affairs organization. These efforts are the building
blocks for Innate’s US affiliate operations and will ensure
continued future development and commercialization of novel
therapeutic options for patients fighting cancer.”
AstraZeneca launched Lumoxiti® in November and
is currently responsible for its commercialization. Per the October
2018 agreement with AstraZeneca, a staged collaborative transition
of operations with AstraZeneca will occur over 2019. Innate Pharma
will take on full responsibility by mid-2020. Filing and launch in
Europe are planned for 2019 and 2021, respectively.
Innate has further strengthened its global
commercial team with the appointment of additional senior
leadership.
Hélène Arditti has joined as a Strategic
Executive Advisor for commercialization to the Innate Executive
Committee. Ms. Arditti brings over 20 years of global marketing and
franchising expertise with a focus in oncology. Most recently
she was the Global Uro-oncology Franchise Senior Vice President and
previously the Endocrinology Marketing Director at Ipsen. In both
of these positions, Ms. Arditti successfully developed the global
launch, life cycle management, and business development strategies
for two oncology products, Decapeptyl® and Cabometyx®.
Guillaume Gimonet has also joined Innate as
Senior Director, Launch Excellence for Lumoxiti. He is responsible
for leading the launch of Lumoxiti across functional teams to
ensure smooth and timely project execution. He was most recently
the Director of Global Program Management and previously the Global
Launch Management Director Oncology at Ipsen in which he secured
Cabometyx® accelerated launch in Renal Cell Cancer.
About Innate Pharma:
Innate Pharma S.A. is a fully integrated
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in
September 2018. Lumoxiti is a first-in class specialty oncology
product for hairy cell leukemia (HCL). Innate Pharma’s broad
pipeline of antibodies includes several first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate Pharma has pioneered the discovery and
development of checkpoint inhibitors, with a unique expertise and
understanding of Natural Killer cell biology. This innovative
approach has resulted in major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a landmark and multi-products partnership
with AstraZeneca/MedImmune.
Based in Marseille, France, Innate Pharma is listed
on Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421IPH9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website www.amf-france.org or on Innate Pharma’s website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate
Pharma Dr. Markus Metzger / Danielle Spangler
/Jérôme Marino Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com |
International Media
Consilium Strategic Communications Mary-Jane
Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com |
|
French Media ATCG
Press Marie Puvieux Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com |